肺泰胶囊联合抗结核西药治疗初治涂阳肺结核的临床效果

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (38 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨肺泰胶囊联合抗结核西药治疗初治涂阳肺结核的效果和安全性。方法选取2016年1月～2018年12月在鹰潭市人民医院铁路分院进行治疗的150 例初治涂阳肺结核患者作为研究对象，通过计算机生成的随机数，将患者随机分为对照组（n=75）和研究组（n=75）。对照组患者予2HRZE/4HR 方案，研究组患者在对照组基础上加用肺泰胶囊治疗。比较两组患者的临床疗效；比较两组患者的痰菌阴转率；比较两组患者的肺部病灶吸收、空洞闭合、临床症状改善情况；比较两组患者的不良反应总发生率。结果研究组患者的治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。研究组患者治疗2、5、6 个月末的痰菌阴转率均高于对照组，差异有统计学意义（P＜0.05）。治疗后，研究组患者的肺部病灶吸收率、空洞闭合率和临床症状改善率均高于对照组，差异有统计学意义（P＜0.05）。研究组患者的病灶吸收时间、空洞闭合时间及临床症状改善时间均短于对照组，差异有统计学意义（P＜0.05）。两组患者的不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论肺泰胶囊联合抗结核西药治疗初治涂阳肺结核的效果确切，安全性好，肺泰胶囊可作为初治涂阳肺结核的辅助治疗方法。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴先辉
	易书林

关键词 ：肺泰胶囊, 肺结核, 痰菌阴转, 不良反应

Abstract：Objective To investigate the effect and safety of Feitai Capsules combined with Western antituberculosis drug in the treatment of preliminary smear-positive pulmonary tuberculosis.Methods From January 2016 to December 2018, 150 patients with newly diagnosed smear-positive pulmonary tuberculosis who were treated in the Yingtan People′s Hospital (Railway Branch) were selected as the research subjects.The patients were randomly divided into the control group (n=75) and study group (n=75) using computer-generated random number.In the control group, 2HRZE/4HR regimen was used, while in the study group, Feitai Capsules on the basis of the control group were added.The clinical efficacy of the two groups was compared.The sputum negative conversion rate of the two groups was compared.The lung lesion absorption, cavity closure and clinical symptom improvement were compared between the two groups.The total incidence of adverse reactions was compared between the two groups.Results The total effective rate in the study group was higher than that in the control group, and the difference was statistically significant (P＜0.05).The sputum negative conversion rate in the study group was higher than that in the control group at the end of 2, 5, and 6 months treatment,the differences were statistically significant(P＜0.05).After treatment,the lung lesion absorption rate,cavity closure rate, and clinical symptom improvement rate in the study group were higher than those in the control group, and the differences were statistically significant (P＜0.05).The lesion absorption time, cavity closure time and clinical symptom improvement time of patients in the study group were all shorter than those in the control group, with statistically significant differences (P＜0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion Feitai Capsules combined with Western antituberculosis drug for the treatment of smear-positive pulmonary tuberculosis are effective and safe.Feitai Capsules can be used as an adjuvant treatment for preliminary smear-positive tuberculosis.

Key words： Feitai Capsules Tuberculosis Sputum negative conversion rate Adverse reactions

基金资助:江西省鹰潭市科学技术局科技计划项目（[2017]2c-50-37）

作者简介: 吴先辉（1977-），男，江西鹰潭人，本科，副主任药师，研究方向：药物治疗

引用本文:

吴先辉; 易书林. 肺泰胶囊联合抗结核西药治疗初治涂阳肺结核的临床效果[J]. 中国当代医药, 2020, 27(13): 137-140.
WU Xian-hui; YI Shu-lin. Clinical effect of Feitai Capsules combined with Western antituberculosis drug in the treatment of preliminary smear-positive pulmonary tuberculosis. 中国当代医药, 2020, 27(13): 137-140.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I13/137

[1]	Kuo HC，Chen SC，Lin HK，et al.Concomitant pediatric abdominal and pulmonary tuberculosis[J].Pediatr Neonatol，2019，60（6）：695-696.
[2]	Li T，Cheng Q，Li C，et al.Evidence for heterogeneity in China′s progress against pulmonary tuberculosis：uneven reductions in a major center of ongoing transmission，2005-2017[J].BMC Infect Dis，2019，19（1）：615.
[3]	Wu DC，Averbukh LD，Wu GY.Diagnostic and therapeutic strategies for peritoneal tuberculosis：a review[J].J Clin Transl Hepatol，2019，7（2）：140-148.
[4]	Teo AKJ，Singh SR，Prem K，et al.Delayed diagnosis and treatment of pulmonary tuberculosis in high-burden countries：a systematic review protocol[J].BMJ Open，2019，9（7）：e029807.
[5]	Kumar NP，Moideen K，Banurekha VV，et al.Plasma proinflammatory cytokines are markers of disease sever ity and bacterial burden in pulmonary tuberculosis[J].Open Forum Infect Dis，2019，6（7）：257.
[6]	中华人民共和国卫生部疾病控制局，中华人民共和国卫生部医政司，中国疾病预防控制中心.中国结核病防治规划实施工作指南（2008年）[M].北京：中国协和医科大学出版社，2008：89.
[7]	符宗望.手术联合抗结核药物与单纯抗结核药物治疗在空洞型肺结核中的效果比较[D].南宁：广西医科大学，2019.
[8]	中华医学会结核病学分会.肺结核诊断和治疗指南[J].中华结核和呼吸杂志，2001，20（2）：70-74.
[9]	Saktiawati AMI，Putera DD，Setyawan A，et al.Diagnosis of tuberculosis through breath test：A systematic review[J].E Bio Med，2019，46：202-214.
[10]	Wang B，Li M，Ma H，et al.Computed tomography-based predictive nomogram for differentiating primary progressive pulmonary tuberculosis from community-acquired pneumonia in children[J].BMC Med Imaging，2019，19（1）：63.
[11]	Alelign A，Petros B，Ameni G.Smear positive tuberculosis and genetic diversity of M.tuberculosis isolates in individuals visiting health facilities in South Gondar Zone，Northwest Ethiopia[J].PLoS One，2019，14（8）：e0216437.
[12]	Kaba O，Kara M，Odacilar CA，et al.Evaluation of cases of pediatric extrapulmonary tuberculosis：a single center experience[J].Turk Pediatri Ars，2019，54（2）：86-92.
[13]	王姬，郑雁，冯马龙.肺泰胶囊联合抗结核治疗方案治疗复治肺结核的临床观察[J].中国中西医结合杂志，2017，37（10）：1196-1200.
[14]	赵晓虎.肺泰胶囊联合常规西药治疗耐药性肺结核49 例[J].中国药业，2014，23（24）：122-124.
[15]	李孝东，周宏宇，李志伟，等.肺结核短程化疗加服肺泰胶囊疗效观察[J].临床肺科杂志，2012，17（11）：2040-2041.